Kit for detecting soluble fms-like tyrosine kinase of placental growth factor
Through the direct spraying and simple drying process of quantum dot fluorescent microsphere labeled antibodies, the problems of cumbersome storage and long detection time of lyophilized markers in the prior art are solved, and the rapid and high sensitivity of PlGF and sFlt-1 are achieved. , suitable for clinical applications.
Patent Information
- Application Number
- CN202411252549.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-06
- Publication Date
- 2024-11-26
AI Technical Summary
The existing market lacks a combination kit that can simultaneously detect placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1), and the preservation and detection process of lyophilized markers of the prior art is cumbersome and energy-consuming.
The PlGF and sFlt-1 antibodies labeled with quantum dot fluorescent microspheres are directly sprayed on the binding pad and stored through a simple drying process. The direct sample is applied for detection. The sample size is small and the time is short, so the PlGF and PlGF can be measured simultaneously. sFlt-1 concentration.
It realizes rapid and simple detection of PlGF and sFlt-1, improves the sensitivity and accuracy of the kit, simplifies the operation process, and makes the kit suitable for storage and transportation at room temperature.
Smart Images

Figure CN119023973A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of fluorescent immunochromatography in medical immunology, in particular to a placenta growth factor soluble fms-like tyrosine kinase detection kit. Background Art
[0002] Abnormal secretion of placental growth factor (PlGF) may be associated with ectopic pregnancy, threatened abortion, preeclampsia, fetal growth restriction and pregnancy-related complications. Detection of the level of placental growth factor in the blood of pregnant women can be used to predict, identify and monitor the treatment of preeclampsia in clinical practice. Soluble fms like tyrosine kinase 1 (sFlt-1) is a glycoprotein with tyrosine kinase activity.
[0003] In the case of uterine placental ischemia and hypoxia, its surface will release excessive anti-angiogenic factor sFlt-1 into the maternal blood circulation, causing vasoconstriction and endothelial damage. Therefore, the clinical value of PlGF / sFlt-1 combined detection in the short-term prediction of preeclampsia has been increasingly widely recognized. Most of the kits on the market are separate PlGF kits. At the same time, there is a large gap in the product market for PlGF / sFlt-1 combined detection. It is more meaningful to use the two combined detection than to use PlGF alone. CN118209720A (invention actual examination) is currently retrieved, and the quantum dot-labeled antibody is freeze-dried into a powder state for long-term storage. Freeze-drying requires pre-freezing-freezing-vacuum drying and other steps. The process is relatively cumbersome and energy-consuming. During the test, 100ul of sample is drawn and added to the freeze-dried marker and mixed for 5min. After mixing, 80ul of the mixture is drawn and added to the sample addition hole for detection. After 10min, the analyzer reads the result. In the present invention, the quantum dot-labeled antibody is directly sprayed on the conjugate pad and then subjected to a simple drying process. During the test, 75ul of sample is directly added to the sample well for testing. The analyzer reads the result after 12 minutes. This is relatively simple, requires less sample, and is fast to test. Summary of the invention
[0004] In view of the above problems, the purpose of the present invention is to provide a placental growth factor soluble fms-like tyrosine kinase detection kit. The present invention directly sprays the PlGF and sFlt-1 antibody complex labeled with quantum dot fluorescent microspheres on the conjugate pad, and streaks the corresponding other antibodies PlGF and sFlt-1 on the NC membrane respectively. The PlGF / sFlt-1 is simultaneously measured by direct sample addition. The present invention can provide a good technical reference for the development of PlGF / sFlt-1 related products to solve the problems raised in the above background technology.
[0005] To achieve the above object, the present invention provides the following technical solutions: a placenta growth factor soluble fms-like tyrosine kinase detection kit, comprising a sample pad, an absorption pad, a binding pad and an NC membrane;
[0006] A quality control line, a test line 1 and a test line 2 are distributed on the NC membrane.
[0007] Preferably, the first test line is placental growth factor, and the second test line is soluble fms-like tyrosine kinase.
[0008] A method for using a placenta growth factor soluble fms-like tyrosine kinase detection kit comprises the following steps:
[0009] The PlGF, sFlt-1 and quality control antibody labeled with quantum dot fluorescent microspheres are prepared into a mixed solution of a certain concentration using a complex diluent, which contains phosphate, bovine serum albumin and preservative components and is sprayed on the binding pad.
[0010] During the test, 75ul of sample is directly added to the sample well of the reaction plate strip, and the PlGF / sFlt-1 result value can be tested after 12 minutes.
[0011] The test reaction principle is that after the sample is added to the sample well, it diffuses to the left through the sample pad by capillary force and flows into the binding pad. The PlGF and sFlt-1 antibody complex labeled with quantum dot fluorescent microspheres sprayed on the binding pad diffuses on the test strip of the nitrocellulose matrix to form a PlGF and sFlt-1 complex, and is captured by another PlGF and sFlt-1 antibody on the test strip to form an antibody-antigen-antibody sandwich complex.
[0012] When there are more PlGF and sFlt-1 antigens in the blood, more antibody sandwich complexes accumulate on the test strip;
[0013] The intensity of the fluorescence signal reflects the amount of captured PlGF and sFlt-1 antigens. After being interpreted by the matching immunofluorescence analyzer, the concentration of PlGF and sFlt-1 antigens in the blood sample can be detected, and the PlGF / sFlt-1 ratio can be obtained based on the values between the two.
[0014] The reading system of the immunofluorescence analyzer comprises:
[0015] Light source system, sample processing system, optical detection system, signal processing and amplification system, data analysis system, feedback control system.
[0016] The light source system includes laser / LED light source selection: selecting a light source with a wavelength that matches the excitation wavelength of the fluorescent dye, and the power of the light source should be high enough to ensure the intensity of the excited fluorescent signal; light source adjustment: through a feedback control system, the intensity and stability of the light source are adjusted in real time to ensure the optimal excitation effect under different samples and dye concentrations;
[0017] The sample processing system includes: High-efficiency antibody labeling: using high-affinity quantum dot fluorescent microspheres to label antibodies to ensure effective recognition and labeling of target antigens and reduce background signals caused by non-specific binding Automated processing: using automated sample processing equipment to achieve accurate sample preparation, staining and elution, reduce manual operation errors, and improve detection consistency;
[0018] The optical detection system includes a high-sensitivity detector: a detector with high quantum efficiency is selected to capture weak fluorescence signals; an optimized optical path design: by optimizing the design of the filter group and the lens group, light loss and noise interference are minimized to ensure efficient transmission of the fluorescence signal; and a multi-channel detection: multi-channel detection is realized, which can collect multiple fluorescence signals at the same time and improve detection throughput and efficiency.
[0019] The signal processing and amplification system comprises:
[0020] Signal amplification: Use a high-gain amplifier circuit to amplify the signal collected by the detector, and use filtering technology to suppress background noise to ensure signal clarity;
[0021] Digital signal processing: Through DSP (digital signal processing) technology, the amplified signal is processed in real time to extract useful fluorescence information and remove noise and interference;
[0022] Assume that the intensity of the amplified signal is S, the original signal is S0, the noise is N, and the amplification factor is G, then:
[0023] S=G·S0
[0024] The signal-to-noise ratio SNR is:
[0025]
[0026] By adjusting G and N, the signal-to-noise ratio can be optimized.
[0027] Preferably, the data analysis system includes: image processing: applying advanced image processing algorithms and using convolutional neural networks to perform background correction, edge detection, and signal separation on fluorescent images to improve signal resolution and quantitative accuracy; performing image processing based on a convolutional neural network model, assuming that the input image is X, the output interpretation result is Y, and the model weight is W, then:
[0028] Y=f(X,W)
[0029] Where f is a combination of convolution operation and activation function;
[0030] Automatic interpretation: Establish an automatic interpretation system based on machine learning, which can automatically judge the test results according to the intensity and distribution pattern of the fluorescence signal and output an analysis report. Suppose the light source intensity is I0 and the fluorescence intensity is I f , then:
[0031] I f =k·I0·ò·C
[0032] Where k is a constant, ò is the excitation efficiency of the fluorescent dye, and C is the concentration of fluorescent molecules in the sample;
[0033] Dynamic adjustment: Automatically adjust light source intensity, detector sensitivity and other parameters based on real-time detection data to ensure optimal detection results under different sample conditions;
[0034] The optimization steps for improving sensitivity specifically include:
[0035] Enhance fluorescence signal: Signal enhancement strategy: Adopt signal enhancement strategy, use metal to enhance fluorescence or multilayer film structure to enhance the emission intensity of fluorescent molecules;
[0036] Long-wavelength fluorescent dyes: Select long-wavelength fluorescent dyes to reduce the interference of background fluorescence and improve the detection signal-to-noise ratio;
[0037] Suppress background signals: Optimize antibody design: Reduce background signals generated by nonspecific binding by designing highly selective binding sites for antibodies;
[0038] Optimization of washing steps: Optimize the washing steps to ensure that unbound fluorescent labeled antibodies are fully washed away and reduce background noise;
[0039] Dynamic adjustment and feedback control: Real-time parameter adjustment: Using the feedback control system, according to the intensity of the fluorescence signal during the detection process, the light source, detector, and sample processing conditions are adjusted in real time to achieve adaptive optimization and ensure high sensitivity and accuracy of each detection
[0040] Compared with the prior art, the present invention has the following beneficial effects:
[0041] This invention sprays the antibody labeled with quantum dot fluorescent microspheres directly on the conjugate pad, and only one sample addition is needed to simultaneously measure PlGF / sFlt-1, and the sample is tested by the direct sample addition method. The sensitivity and accuracy of the test kit during the experiment are improved, and the operation process of the experiment is simpler and more convenient, and the test kit can be stored and transported at room temperature.
[0042] 1. Quantum dot immunofluorescence chromatography is similar to colloidal gold immunochromatography, with the advantages of short reaction time, small detection equipment and bedside detection.
[0043] 2. Quantum dot immunochromatography technology uses quantum dots as tracer markers in immunochromatography. On the one hand, it uses the unique fluorescence of quantum dots as observation signals, which has the advantages of high sensitivity, low interference and rapidity. On the other hand, it uses the advantages of immunochromatography technology such as simplicity, strong specificity and low cost.
[0044] 3. It is inexpensive to prepare, has good stability, and is easy to store. It uses the advantages of high sensitivity and strong specificity in detection using the quantum dot fluorescent microsphere labeling method, and is relatively easy to promote in clinical practice.
[0045] 4. Quantum dot fluorescent microspheres have high luminescence performance, excellent optical stability, and good signal-to-noise ratio, making ultra-sensitive project testing possible. As a new type of quantum dot material, its sensitivity is comparable to that of the chemiluminescence platform.
[0046] In summary, quantum dots concentrate a large number of optical properties, which makes quantum dots show great value and prospects in diversified, high-sensitivity, and high-stability analysis and research. Similarly, this also makes the future prospects of the new quantum dot immunofluorescence chromatography immeasurable. This new immunochromatographic analysis method can be extended to related fields such as food analysis and clinical testing. BRIEF DESCRIPTION OF THE DRAWINGS
[0047] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0048] Figure 1 It is a structural diagram of the kit of the present invention;
[0049] Figure 2 The present invention is a flow chart of the method for using a placenta growth factor soluble fms-like tyrosine kinase detection kit.
[0050] Figure 3 This is a PLGF consistency test diagram of the present invention;
[0051] Figure 4 This is a diagram of the sFlt-1 consistency experiment of the present invention;
[0052] Figure 5 This is a structural diagram of the test strip of the present invention.
[0053] Description of reference numerals:
[0054] 1. Sample pad; 2. Absorption pad; 3. Binding pad; 4. NC membrane; 5. Quality control line; 6. Test line one; 7. Test line two. DETAILED DESCRIPTION
[0055] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0056] See also Figures 1 to 5 , the present invention provides a technical solution:
[0057] A placenta growth factor soluble fms-like tyrosine kinase detection kit comprises a sample pad 1, an absorption pad 2, a binding pad 3 and an NC membrane 4;
[0058] The NC membrane 4 is provided with a quality control line 5 , a test line 1 6 and a test line 2 7 .
[0059] The test line 1 6 is placental growth factor, and the test line 2 7 is soluble fms-like tyrosine kinase.
[0060] A method for using a placenta growth factor soluble fms-like tyrosine kinase detection kit comprises the following steps:
[0061] The PlGF, sFlt-1 and quality control antibody labeled with quantum dot fluorescent microspheres are prepared into a mixed solution of a certain concentration using a complex diluent, which contains phosphate, bovine serum albumin and preservative components and is sprayed on the binding pad.
[0062] During the test, 75ul of sample is directly added to the sample well of the reaction plate strip, and the PlGF / sFlt-1 result value can be tested after 12 minutes.
[0063] The test reaction principle is that after the sample is added to the sample well, it diffuses to the left through the sample end of the sample pad 1 by capillary force and flows into the binding pad 3. The PlGF and sFlt-1 antibody complex labeled with quantum dot fluorescent microspheres sprayed on the binding pad 3 diffuses on the test strip of the nitrocellulose matrix to form a PlGF and sFlt-1 complex, and is captured by another PlGF and sFlt-1 antibody on the test strip to form an antibody-antigen-antibody sandwich complex.
[0064] When there are more PlGF and sFlt-1 antigens in the blood, more sandwich complexes accumulate on the test strip;
[0065] The intensity of the fluorescence signal reflects the amount of captured PlGF and sFlt-1 antigens. After being interpreted by the matching immunofluorescence analyzer, the concentration of PlGF and sFlt-1 antigens in the blood sample can be detected, and the PlGF / sFlt-1 ratio can be obtained based on the values between the two.
[0066] The reading system of the immunofluorescence analyzer comprises:
[0067] Light source system, sample processing system, optical detection system, signal processing and amplification system, data analysis system, feedback control system.
[0068] The light source system includes laser / LED light source selection: selecting a light source with a wavelength that matches the excitation wavelength of the fluorescent dye, and the power of the light source should be high enough to ensure the intensity of the excited fluorescent signal; light source adjustment: through a feedback control system, the intensity and stability of the light source are adjusted in real time to ensure the optimal excitation effect under different samples and dye concentrations;
[0069] The sample processing system includes: High-efficiency antibody labeling: using high-affinity quantum dot fluorescent microspheres to label antibodies to ensure effective recognition and labeling of target antigens and reduce background signals caused by non-specific binding Automated processing: using automated sample processing equipment to achieve accurate sample preparation, staining and elution, reduce manual operation errors, and improve detection consistency;
[0070] The optical detection system includes a high-sensitivity detector: a detector with high quantum efficiency is selected to capture weak fluorescence signals; an optimized optical path design: by optimizing the design of the filter group and the lens group, light loss and noise interference are minimized to ensure efficient transmission of the fluorescence signal; and a multi-channel detection: multi-channel detection is realized, which can collect multiple fluorescence signals at the same time and improve detection throughput and efficiency.
[0071] The signal processing and amplification system comprises:
[0072] Signal amplification: Use a high-gain amplifier circuit to amplify the signal collected by the detector, and use filtering technology to suppress background noise to ensure signal clarity;
[0073] Digital signal processing: Through DSP (digital signal processing) technology, the amplified signal is processed in real time to extract useful fluorescence information and remove noise and interference;
[0074] Assume that the intensity of the amplified signal is S, the original signal is S0, the noise is N, and the amplification factor is G, then:
[0075] S=G·S0
[0076] The signal-to-noise ratio SNR is:
[0077]
[0078] By adjusting G and N, the signal-to-noise ratio can be optimized.
[0079] The data analysis system includes: Image processing: applying advanced image processing algorithms and using convolutional neural networks to perform background correction, edge detection, and signal separation on fluorescent images to improve signal resolution and quantitative accuracy; image processing based on a convolutional neural network model, assuming that the input image is X, the output judgment result is Y, and the model weight is W, then:
[0080] Y=f(X,W)
[0081] Where f is a combination of convolution operation and activation function;
[0082] Automatic interpretation: Establish an automatic interpretation system based on machine learning, which can automatically judge the test results according to the intensity and distribution pattern of the fluorescence signal and output an analysis report. Suppose the light source intensity is I0 and the fluorescence intensity is I f , then:
[0083] I f =k·I0·ò·C
[0084] Where k is a constant, ò is the excitation efficiency of the fluorescent dye, and C is the concentration of fluorescent molecules in the sample;
[0085] Dynamic adjustment: Automatically adjust light source intensity, detector sensitivity and other parameters based on real-time detection data to ensure optimal detection results under different sample conditions;
[0086] The optimization steps for improving sensitivity specifically include:
[0087] Enhance fluorescence signal: Signal enhancement strategy: Adopt signal enhancement strategy, use metal to enhance fluorescence or multilayer film structure to enhance the emission intensity of fluorescent molecules;
[0088] Long-wavelength fluorescent dyes: Select long-wavelength fluorescent dyes to reduce the interference of background fluorescence and improve the detection signal-to-noise ratio;
[0089] Suppress background signals: Optimize antibody design: Reduce background signals generated by nonspecific binding by designing highly selective binding sites for antibodies;
[0090] Optimization of washing steps: Optimize the washing steps to ensure that unbound fluorescent labeled antibodies are fully washed away and reduce background noise;
[0091] Dynamic adjustment and feedback control: Real-time parameter adjustment: Using the feedback control system, the light source, detector, and sample processing conditions are adjusted in real time according to the intensity of the fluorescence signal during the detection process to achieve adaptive optimization and ensure high sensitivity and accuracy of each detection.
[0092] Experiment 1. Preparation of a placental growth factor soluble fms-like tyrosine kinase detection kit
[0093] Screen high-quality monoclonal antibodies, conduct pairing experiments, and screen out capture antibodies and detection antibodies with high specificity and good affinity. Use coating diluent to adjust the concentration of PLGF detection antibody to 2 mg / mL, sFlt-1 detection antibody to 2 mg / mL, and Chicken IgY to 1 mg / mL.
[0094] Antibody coating: prepare the nitrocellulose membrane and place it correctly on the film sticking device, stick the nitrocellulose membrane on the pad card, use the spraying device to spray 1 mg / mL Chicken IgY adjusted with the coating diluent on the nitrocellulose membrane to form a quality control line, forming the first test line, spray 2 mg / mL PLGF solution adjusted with the coating diluent on the nitrocellulose membrane to form the second test line, spray 2 mg / mL sFlt-1 detection antibody adjusted with the coating diluent on the nitrocellulose membrane to form the third test line, and obtain the coated reagent strip, wherein the spraying amount of the spraying device is 1 μL / cm, the spraying speed is 9 cm / s, the test line and the quality control line are sprayed in parallel on the nitrocellulose membrane for coating, and the interval between each test line and between the quality control line and the first test line is 3 mm, and then placed in an oven and dried at 37°C for 3 days.
[0095] Preparation of quantum dot antibody complex: The selected PLGF labeled antibody was prepared with 1×PBS to 2 mg / mL. Dissolve the quantum dot fluorescent microspheres in activation buffer (50mM / L MES pH = 6.0) according to the volume ratio of quantum dot fluorescent microspheres: activation buffer (1:9), mix well, centrifuge at 16000r for 20min, and discard the supernatant. Add activation buffer to re-dissolve the microspheres, then add NHS and EDC (mass ratio is 9:1, NHS and EDC are configured with activation buffer to a concentration of 10mg / mL, EDC: microsphere carboxyl = 1:2.5) and rotate in the dark for 30min, centrifuge and remove the supernatant. Add 5mM / L MES pH = 6.5 coupling buffer to wash twice, then add coupling buffer to re-dissolve the microspheres, add labeled antibody at a final antibody concentration of 0.1mg / mL, rotate and shake in the dark for 2h, and centrifuge to remove the supernatant. Then, add blocking agent (1% bovine serum albumin + 0.1% glycine by mass) to dissolve, shake in the dark for 2 hours, and centrifuge to remove the supernatant. Finally, add preservation solution (20mM / LTirs buffer at pH=8.0) to wash once, then centrifuge and dissolve in preservation solution again at 2-8°C for storage. The preparation method of sFlt-1 quantum dot complex and quality control complex is the same as above.
[0096] Preparation of conjugate pad: PLGF complex, sFlt-1 complex and Anti-IgY complex labeled with quantum dot fluorescent microspheres were sprayed on the conjugate pad, and then placed in an oven and dried at 37°C for 1 day. The conjugate pad was sprayed using a gold label sprayer, with a spray pad speed of 5±1cm / sec, a spray volume of 4±0.8μL / cm, a spray pad pressure of 0.02±0.004Mpa, a spray pad height of 4.6±0.9mm, and a spray concentration of PLGF complex and sFlt-1 complex of 10ug / mL.
[0097] Reagent strip filming and cutting: stick the conjugate pad correctly on the wide side of the pad card, requiring the pad to press 1.5mm on the nitrocellulose membrane, stick the sample pad behind the conjugate pad, and stick the absorption pad on the narrow side of the other end of the pad card, requiring the pad to press above the nitrocellulose membrane and 0.5mm from the outer edge of the bottom plate. Set the cutting width of the cutting equipment to 3mm and confirm whether the cut surface is flat.
[0098] Reagent strip assembly: correctly install the cut test strips on the bottom shell, the absorbent pad should be installed at the end of the shell, close the upper shell, place it on the shell pressing device and press it firmly to obtain the reaction plate (reagent strip) for use.
[0099] Add formula and make ID chip: take the reaction plate, buffer solution, PLGF and sFlt-1 calibrators that have passed the intermediate product test. Each calibrator has at least 5 concentrations and each concentration is tested at least 5 times. Make a standard curve with the average value of the area scan graph of each concentration calibrator and the concentration to get the linear equation. Import the numerical value of the equation into the dedicated software, connect the blank original chip to the computer, import the numerical code into the chip through the dedicated software, and affix the chip label.
[0100] Experiment 2. Experimental methods:
[0101] The kit of this application was tested using the Suzhou Hemai Precision Instrument Co., Ltd. fluorescent immunoassay analyzer (model: FIC-Q1) that is compatible with the kit of this application. The FIC-Q1 operation steps are as follows:
[0102] 1) Open the reaction plate packaging bag, take out the reaction plate and place it horizontally.
[0103] 2) Use a pipette to take 75 μL of sample (serum, plasma and whole blood) into the sample well of the reaction plate.
[0104] 3) React at room temperature for 12 minutes.
[0105] 4) Insert the reaction plate after reaction into the special detection equipment for testing.
[0106] Experiment 3. Precision test
[0107] The experimental materials are shown in Table 1. The experimental process was carried out according to the operating steps of the experimental method in Experiment 2.
[0108] Table 1 Concentration of test materials
[0109]
[0110] Table 2PLGF test results
[0111] Serial number Low test results (pg / mL) High value test result (pg / mL) 1 58.82 953.83 2 62.95 1046.21 3 62.77 1022.04 4 57.90 1048.09 5 60.87 913.38 6 62.74 1043.89 7 66.92 995.65 8 59.20 1043.71 9 58.67 1090.10 10 67.10 1016.89 11 68.62 1039.34 12 60.27 1016.10 13 58.32 1083.45 14 64.84 1055.55 15 65.18 1035.74 16 62.52 1091.73 17 57.45 999.56 18 68.48 920.14 19 65.79 907.86 20 62.05 947.29 average value 62.57 1013.53 Standard Deviation 3.62 57.29 CV 5.78 5.65
[0112] Table 3 sFlt-1 detection results
[0113] Serial number Low test results (pg / mL) High value test result (pg / mL) 1 95.88 1819.04 2 110.01 2176.38 3 100.46 2099.84 4 100.65 2136.19 5 109.39 2023.02 6 102.75 1915.78 7 90.19 1833.38 8 107.22 2051.37 9 93.87 1868.54 10 102.15 1956.33 11 95.94 1948.91 12 106.47 2000.10 13 96.55 2021.01 14 107.18 1985.51 15 92.87 2186.78 16 96.56 2037.60 17 91.41 2150.30 18 94.67 2048.72 19 93.06 2152.13 20 100.32 1897.09 average value 99.38 2015.40 Standard Deviation 6.20 113.11 CV 6.24 5.61
[0114] As shown in Tables 2 and 3, the low and high value quality control products of PLGF and sFlt-1 were measured 20 times and the average value, standard deviation and CV were calculated. The results show that the kit of the present application has a CV of 5.78% when measuring the low value sample of PLGF and a CV of 5.65% for the high value sample; when measuring the low value sample of sFlt-1, the CV is 6.24% and the CV is 5.61% for the high value sample. The CV values of the two items are both less than 10%, indicating that the kit prepared by the present application has good precision, is suitable for clinical testing, and meets the differentiated needs of different customers in different testing occasions.
[0115] Experiment 4. Accuracy test
[0116] 1. Test materials:
[0117] PLGF and sFlt-1 are certified standard substances with concentrations of 100pg / mL and 500pg / mL pg / mL respectively.
[0118] 2. Experimental testing process
[0119] Perform the test according to the operating steps of the experimental method in Experiment 2.
[0120] Table 4 Relative deviation of PLGF and sFlt-1 detection
[0121]
[0122] As can be seen from Table 4, after repeated determination of PLGF and sFlt-1 two certified reference materials for three times, the relative deviations were calculated respectively. From the obtained results, it can be seen that the relative deviation of the kit of the present application when determining the certified reference material of PLGF is -0.44% to 1.42%; the relative deviation when determining the certified reference material of sFlt-1 is -1.66% to 4.31%. The relative deviations of the detection of the two items are both less than 5%, indicating that the kit prepared by the present invention has good accuracy, is suitable for clinical detection, and meets the differentiated needs of different customers in different detection occasions.
[0123] Experiment 5. Consistency test
[0124] 1. Test materials:
[0125] Clinical samples were provided by relevant hospitals, of which 60 PLGF and 60 sFlt-1 samples were valued by Zhonghan Shengtai immunofluorescence method, including plasma and homologous whole blood. The distribution range of PLGF content was 15-4000pg / mL, and the distribution range of sFlt-1 content was 10pg / mL-12000pg / mL.
[0126] 2. Experimental testing process
[0127] Perform the test according to the operating steps of the experimental method in Experiment 2.
[0128] 3. Analysis of test results:
[0129] According to the experimental method, 60 samples with immunofluorescence method were tested, and the correlation of each sample type was analyzed based on the serum test results.
[0130] The test results are shown in Figure 3-Figure 5 shown.
[0131] Depend on Figure 3 It can be seen that the PLGF serum test value of the control system is the X-axis and the PLGF serum test value of the experimental system is the Y-axis, and a scatter plot is drawn to perform correlation analysis. 60 clinical PLGF serum samples were tested, and the average relative deviation of the samples was less than 10%, R 2 ≧0.98, and the slope is in the range of 0.9 to 1.1, indicating that the kit prepared in this application has good consistency with the immunofluorescence method in detecting PLGF serum; with the PLGF plasma detection value of the control system as the X-axis and the PLGF plasma detection value of the experimental system as the Y-axis, a scatter plot is drawn for correlation analysis. 60 clinical PLGF plasma samples were tested, and the average relative deviation of the samples was less than 10%, R 2 ≧0.98, and the slope is in the range of 0.9 to 1.1, indicating that the kit prepared in this application has good consistency with the immunofluorescence method in detecting PLGF plasma; with the control system PLGF whole blood detection value as the X-axis and the experimental system PLGF whole blood detection value as the Y-axis, a scatter plot is drawn for correlation analysis. 60 clinical PLGF whole blood samples were tested, and the average relative deviation of the samples was less than 10%, R 2 ≧0.98, and the slope is in the range of 0.9 to 1.1, indicating that the kit prepared in the present application has good consistency with the immunofluorescence method in detecting PLGF in whole blood.
[0132] Depend on Figure 3 It can be seen that the sFlt-1 serum test value of the control system is the X-axis and the sFlt-1 serum test value of the experimental system is the Y-axis, and a scatter plot is drawn to perform correlation analysis. 60 clinical sFlt-1 serum samples were tested, and the average relative deviation of the samples was less than 10%, R 2 ≧0.98, and the slope is in the range of 0.9 to 1.1, indicating that the kit prepared in this application has good consistency with the immunofluorescence method in detecting sFlt-1 serum; with the sFlt-1 plasma detection value of the control system as the X-axis and the sFlt-1 plasma detection value of the experimental system as the Y-axis, a scatter plot is drawn for correlation analysis. 60 clinical sFlt-1 plasma samples were tested, and the average relative deviation of the samples was less than 10%, R 2≧0.98, the slope is in the range of 0.9 to 1.1, indicating that the kit prepared in this application has good consistency with the immunofluorescence method in detecting sFlt-1 plasma; with the control system sFlt-1 whole blood detection value as the X-axis and the experimental system sFlt-1 whole blood detection value as the Y-axis, a scatter plot is drawn for correlation analysis. 60 clinical sFlt-1 whole blood samples were tested, and the average relative deviation of the samples was less than 10%, R2≧0.98, and the slope was in the range of 0.9 to 1.1, indicating that the kit prepared in this application has good consistency with the immunofluorescence method in detecting sFlt-1 whole blood.
[0133] Experiment 6. Performance comparison between the strip with binding pad and the existing kit with detection substance
[0134] In order to illustrate the performance difference between the test kit with the substance to be tested and the test kit with the detection substance, a performance comparison test study is now conducted.
[0135] 1. Test materials:
[0136] Clinical plasma samples were provided by relevant hospitals, of which 20 PLGF samples were valued by Zhonghan Shengtai immunofluorescence method, and 20 sFlt-1 samples were valued by Zhonghan Shengtai immunofluorescence method. The distribution range of PLGF content was 10-4000ng / mL, and the distribution range of sFlt-1 content was 10-12000pg / mL.
[0137] PLGF kits and sFlt-1 kits with detection substances from two manufacturers and their supporting instruments were purchased from relevant agents.
[0138] 2. Test methods:
[0139] The kit of this application was tested for consistency using the Suzhou Hemai Precision Instrument Co., Ltd. fluorescent immunoassay analyzer (model: FIC-Q1) that is compatible with the kit of this application, and each item and each sample were tested 5 times. At the same time, 20 plasma samples were tested simultaneously using the PLGF kit and sFlt-1 kit with detection substances from two manufacturers, and each item and each sample were tested 5 times. The FIC-Q1 operation steps are as follows:
[0140] 1) Open the reaction plate packaging bag, take out the reaction plate and place it horizontally.
[0141] 2) Use a pipette to take 75 μL of sample (serum, plasma and whole blood) into the sample well of the reaction plate.
[0142] 3) React at room temperature for 12 minutes.
[0143] 4) Insert the reaction plate after reaction into the special detection equipment for testing.
[0144] 3. Analysis of test results:
[0145] Twenty plasma samples were tested according to the experimental method, and the differences between the two methods were analyzed.
[0146] The test results are shown in Tables 5 and 6.
[0147] Table 5 Comparison of PLGF test results [Unit: ng / mL]
[0148]
[0149]
[0150] Table 6 Comparison of sFlt-1 test results [Unit: pg / mL]
[0151]
[0152] As shown in Table 5, 20 PLGF plasma samples were simultaneously detected using a kit with a detection substance and a kit of the present application. When the kit with a detection substance was used to test low-concentration PLGF plasma samples, the precision CV value of individual samples was ≧10%, and the relative deviation was ≧10%, while the precision CV of the kit of the present application was ≤10% and the relative deviation was ≤10% within the detection range of 10-4000pg / mL, indicating that the patented kit has good performance and meets the needs of clinical detection of PLGF.
[0153] As shown in Table 6, 20 sFlt-1 plasma samples were simultaneously tested using the kit with detection substance and the kit of this patent. When testing low-concentration sFlt-1 plasma samples with the kit with detection substance, the precision CV value of individual samples was ≧10%, while the precision CV of the kit of this patent was ≤10% within the detection range of 10-12000pg / mL, and the relative deviation was ≤10%, indicating that the performance of the kit of this patent is good and meets the needs of clinical detection of sFlt-1.
[0154] The performance indicators, sample types and response times of this application are shown in Table 9.
[0155] Table 9 Performance indicators
[0156]
[0157] Although the embodiments of the present invention have been disclosed as above, they are not limited to the applications listed in the specification and the implementation modes, and they can be fully applied to various fields suitable for the present invention. For those familiar with the art, additional modifications can be easily implemented. Therefore, without departing from the general concept defined by the claims and the scope of equivalents, the present invention is not limited to the specific details and the illustrations shown and described herein.
Claims
1. A placental growth factor soluble fms-like tyrosine kinase detection kit, characterized in that: It includes a sample pad (1), an absorption pad (2), a binding pad (3) and an NC membrane (4); A quality control line (5), a test line 1 (6) and a test line 2 (7) are distributed on the NC membrane (4).
2. A placenta growth factor soluble fms-like tyrosine kinase detection kit according to claim 1, characterized in that: The test line one (6) is placental growth factor, and the test line two (7) is soluble fms-like tyrosine kinase.
3. A method for using a placental growth factor soluble fms-like tyrosine kinase detection kit according to claims 1-2, characterized in that: The steps include: The PlGF, sFlt-1 and quality control antibody labeled with quantum dot fluorescent microspheres are prepared into a mixed solution of a certain concentration using a complex diluent, which contains phosphate, bovine serum albumin and preservative components and is sprayed on the binding pad.
4. The method for using a placenta growth factor soluble fms-like tyrosine kinase detection kit according to claim 3, characterized in that: During the test, 75ul of sample is directly added to the sample well of the reaction plate strip, and the PlGF / sFlt-1 result value can be tested after 12 minutes.
5. The method for using a placenta growth factor soluble fms-like tyrosine kinase detection kit according to claim 4, characterized in that: The test reaction principle is that after the sample is added to the sample loading hole, it diffuses to the left through the sample loading end of the sample pad (1) by capillary force and flows into the binding pad (3), and the PlGF and sFlt-1 antibody complex labeled with quantum dot fluorescent microspheres sprayed on the binding pad (3) diffuses on the test strip of the nitrocellulose matrix to form a PlGF and sFlt-1 complex, and is captured by another PlGF and sFlt-1 antibody on the test strip to form a quantum dot fluorescent microsphere labeled antibody-antigen-antibody sandwich complex.
6. The method for using the placenta growth factor soluble fms-like tyrosine kinase detection kit according to claim 5, characterized in that: When there are more PlGF and sFlt-1 antigens in the blood, more antibody sandwich complexes accumulate on the test strip; The intensity of the fluorescence signal reflects the amount of captured PlGF and sFlt-1 antigens. After being interpreted by the matching immunofluorescence analyzer, the concentration of PlGF and sFlt-1 antigens in the blood sample can be detected, and the PlGF / sFlt-1 ratio can be obtained based on the values between the two.
7. The method for using the placenta growth factor soluble fms-like tyrosine kinase detection kit according to claim 6, characterized in that: The reading system of the immunofluorescence analyzer comprises: Light source system, sample processing system, optical detection system, signal processing and amplification system, data analysis system, feedback control system.
8. The method for using the placenta growth factor soluble fms-like tyrosine kinase detection kit according to claim 6, characterized in that: The light source system includes laser / LED light source selection: selecting a light source with a wavelength that matches the excitation wavelength of the fluorescent dye, and the power of the light source should be high enough to ensure the intensity of the excited fluorescent signal; light source adjustment: through a feedback control system, the intensity and stability of the light source are adjusted in real time to ensure the optimal excitation effect under different samples and dye concentrations; The sample processing system includes: High-efficiency antibody labeling: using high-affinity quantum dot fluorescent microspheres to label antibodies to ensure effective recognition and labeling of target antigens and reduce background signals caused by non-specific binding Automated processing: using automated sample processing equipment to achieve accurate sample preparation, staining and elution, reduce manual operation errors, and improve detection consistency; The optical detection system includes a high-sensitivity detector: a detector with high quantum efficiency is selected to capture weak fluorescence signals; an optimized optical path design: by optimizing the design of the filter group and the lens group, light loss and noise interference are minimized to ensure efficient transmission of the fluorescence signal; and a multi-channel detection: multi-channel detection is realized, which can collect multiple fluorescence signals at the same time and improve detection throughput and efficiency.
9. The method for using a placenta growth factor soluble fms-like tyrosine kinase detection kit according to claim 6, characterized in that: The signal processing and amplification system comprises: Signal amplification: Use a high-gain amplifier circuit to amplify the signal collected by the detector, and use filtering technology to suppress background noise to ensure signal clarity; Digital signal processing: Through DSP (digital signal processing) technology, the amplified signal is processed in real time to extract useful fluorescence information and remove noise and interference; Assume that the intensity of the amplified signal is S, the original signal is S0, the noise is N, and the amplification factor is G, then: S=G·S0 The signal-to-noise ratio SNR is: By adjusting G and N, the signal-to-noise ratio can be optimized.
10. The method for using the placenta growth factor soluble fms-like tyrosine kinase detection kit according to claim 6, characterized in that: The data analysis system includes: Image processing: applying advanced image processing algorithms and using convolutional neural networks to perform background correction, edge detection, and signal separation on fluorescent images to improve signal resolution and quantitative accuracy; image processing based on a convolutional neural network model, assuming that the input image is X, the output judgment result is Y, and the model weight is W, then: Y=f(X,W) Where f is a combination of convolution operation and activation function; Automatic interpretation: Establish an automatic interpretation system based on machine learning, which can automatically judge the test results according to the intensity and distribution pattern of the fluorescence signal and output an analysis report. Suppose the light source intensity is I0 and the fluorescence intensity is I f , then: I f =k·I0·ò·C Where k is a constant, ò is the excitation efficiency of the fluorescent dye, and C is the concentration of fluorescent molecules in the sample; Dynamic adjustment: Automatically adjust light source intensity, detector sensitivity and other parameters based on real-time detection data to ensure optimal detection results under different sample conditions; The optimization steps for improving sensitivity specifically include: Enhance fluorescence signal: Signal enhancement strategy: Adopt signal enhancement strategy, use metal to enhance fluorescence or multilayer film structure to enhance the emission intensity of fluorescent molecules; Long-wavelength fluorescent dyes: Select long-wavelength fluorescent dyes to reduce the interference of background fluorescence and improve the detection signal-to-noise ratio; Suppress background signals: Optimize antibody design: Reduce background signals generated by nonspecific binding by designing highly selective binding sites for antibodies; Optimization of washing steps: Optimize the washing steps to ensure that unbound fluorescent labeled antibodies are fully washed away and reduce background noise; Dynamic adjustment and feedback control: Real-time parameter adjustment: Using the feedback control system, the light source, detector, and sample processing conditions are adjusted in real time according to the intensity of the fluorescence signal during the detection process to achieve adaptive optimization and ensure high sensitivity and accuracy of each detection.
